A hepatitis C virus nonstructural protein 5A inhibitor.

Phase of research

Potential treatment - pre-clinical evidence

How it helps


Drug status

Used to treat other disease

Supporting references
Contradictory references
AI-suggested references
Clinical trials

General information

Elbasvir is a heterotetracyclic hepatitis C virus (HCV) nonstructural protein 5A inhibitor. It is used for the treatment of chronic HCV infection in a combined therapy (ChEBI).

Elbasvir on DrugBank
Elbasvir on PubChem
Elbasvir on Wikipedia

Marketed as

ZEPATIER (in a fixed dose with GRAZOPREVIR)


Structure image - Elbasvir


Supporting references

Link Tested on Impact factor Notes Publication date
CSF3 Is a Potential Drug Target for the Treatment of COVID-19
Small molecule In vitro In silico
16+ years old volunteers 3.37

Decreased host CSF3 protein expression in vitro and was predicted to inhibit it. CSF3 was computationally modelled to represent a drug target for the treatment of COVID-19.

Combined in silico and in vitro approaches identified the antipsychotic drug lurasidone and the antiviral drug elbasvir as SARS-CoV2 and HCoV-OC43 inhibitors
RdRpol Small molecule In vitro In silico
in silico; Huh 7-hACE2 cells 4.10

Inhibited SARS-CoV-2 infection in a high content microscopy assay with an EC50 of ca. 23 μM and high selectivity (CC50 of ca. 118). The drug also displayed efficacy in a viral yield reduction assay with an estimated EC50 of >1000 μM. Based on computational modelling, the antiviral activity stems from RNA-dependent RNA polymerase inhibition.


AI-suggested references